Clinical trials: Dementia, Lewy Body
Lewy Body Dementia (LBD), Alzheimer Dementia (AD)
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias
This study is being done to research the usefulness of PET/CT imaging for measuring brain inflammation and its relation to Alzheimer's Disease Dementia and related dementias.
- Trial name
- NCT04786223
- Testing
- C-11 ER-176, Blood Test
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Val Lowe
REM Sleep Behavior Disorder, Parkinson Disease
North American Prodromal Synucleinopathy Consortium Stage 2
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies
- Trial name
- NAPS2 (NCT05826457)
- Where
- 9 sites in United States, Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Dementia
Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia
This study will employ a double-blind, placebo-controlled approach to assess the effect of 1072nm infrared (IR) phototherapy on the behavioral and cognitive symptoms associated with early and mid-stage dementia.
- Trial name
- NCT01059877
- Testing
- 1072nm infrared Photobiomodulation, Photobiomodulation SIMULATED
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Quietmind Foundation
Lewy Body Disease, Lewy Body Dementia
Visual Hallucinations in Lewy Body Diseases
The goal of this basic experimental study involving humans (BESH) protocol is to improve the understanding of neural mechanisms underlying visual hallucinations in Lewy Body diseases to inform future treatment developments.
- Conditions
- Lewy Body Disease, Lewy Body Dementia, Parkinson Disease, Parkinson Disease Dementia
- Trial name
- NCT07849413
- Testing
- Behavioral Tasks, MRI/MEG Scans
- Where
- United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Parkinson Disease, Multiple System Atrophy
Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease
To determine whether retinal abnormalities, as measured by high definition optical coherence tomography (HD-OCT) and visual electrophysiology techniques can be used as a clinical biomarker to monitor disease progression overtime…
- Conditions
- Parkinson Disease, Multiple System Atrophy, REM Sleep Behavior Disorder, Pure Autonomic Failure
- Trial name
- NCT02640339
- Where
- United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Parkinson Disease, REM Sleep Behavior Disorder
Prospective Neuroimaging Investigation of Idiopathic REM Sleep Behavior Disorder
This is a prospective cohort study to evaluate degenerative changes in the brain by performing functional imaging analysis in patients with RBD and its correlations with clinical symptoms and dopaminergic degeneration.
- Trial name
- NCT02984137
- Testing
- testing, evaluation, sampling
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Dementia With Lewy Bodies, Degeneration Nerves
Visualising Cerebral and Peripheral Cholinergic Nerves in Patients With Dementia Lewy Bodies.
Lewy Body Dementia (DLB) is the second most common type of neurodegenerative dementia and characterized by loss of cholinergic neurons in the cerebrum and possibly also internal organs.
- Conditions
- Dementia With Lewy Bodies, Degeneration Nerves, Positron-Emission Tomography, Acetylcholine
- Trial name
- NCT04291144
- Testing
- PET-CT using FEOBV, MRI-scan, Cognitive assessment
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Alpha-Synucleinopathy, Parkinson's Disease
Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain
The overall goal of this protocol is to evaluate [18F]MNI-1216 (also known as [18F]ACI-12589) as an α-synuclein targeted radiopharmaceutical in 3 parts as follows: Part 1: first in human (FiH) imaging Optional Part 2: expansion…
- Conditions
- Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy
- Trial name
- NCT06445465
- Testing
- [18F]MNI-1216
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Invicro
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
This multicenter study aims to characterize the language profiles of patients with various neurodegenerative diseases, including Alzheimer's disease (AD), Primary Progressive Aphasia (PPA), behavioral variant Frontotemporal…
- Conditions
- Alzheimer's Disease (AD), Frontotemporal Dementia (FTD), Parkinsons Disease (PD), Lewy Body Dementia
- Trial name
- AILAN (NCT07906769)
- Testing
- Speech and language Test to support clinical diagnosis
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Parkinson Disease, MSA - Multiple System Atrophy
Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease
Clinical diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) is challenging, especially in the early stages.
- Conditions
- Parkinson Disease, MSA - Multiple System Atrophy, Lewy Body Dementia (LBD), Neurodegenerative Disease
- Trial name
- EXTRAORDINARY (NCT06846658)
- Where
- 3 sites in Italy
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Alzheimer Disease, Dementia Alzheimers
Optical Coherence Tomography in Cerebral Amyloidosis
In this observational study, the investigators aim to evaluate whether changes in the retinal and choroidal circulation, as assessed by Optical Coherence Tomography (OCT) and the quantification of retinal amyloid deposits using…
- Conditions
- Alzheimer Disease, Dementia Alzheimers, Dementia, Lewy Body Disease
- Trial name
- NCT03472482
- Testing
- non-invasive retinal imaging
- Where
- Belgium
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Alzheimer Disease (AD), Frontotemporal Lobar Degeneration
ADDIA Proof-of-Performance Clinical Study
The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease (AD), Frontotemporal Lobar Degeneration, Dementia with Lewy Bodies (DLB), Parkinson Disease Dementia (PDD)
- Trial name
- ADDIA (NCT03030586)
- Testing
- volumetric MRI
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 821 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Lewy Body Disease, Healthy Aging
Language and Lewy Body Diseases: Sentence Comprehension Problems and Modifying Noninvasive Brain Stimulation Treatment
Lewy body diseases (LBDs) represents a group of neurodegenerative disorders characterized by the abnormal accumulation of aggregates of α-synuclein protein leading to the formation of Lewy bodies (LB) and Lewy neurites resulting…
- Trial name
- LANG-LBD (NCT05847985)
- Testing
- transcranial direct current stimulation (tDCS)
- Where
- Czechia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Masaryk University
Lewy Body Disease
A Phase I Study of GT300 in Healthy Subjects
Descriptive safety and pharmacokinetics of GT300, exploratory biomarker effects for the evaluation of the effect of GT300 on the autophagy-lysosomal pathway (ALP), food effect on PK and fasting effect on biomarkers.
- Trial name
- NCT04963855
- Testing
- GT300, Microcrystalline cellulose
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Generian Pharmaceuticals, Inc.
Mild Cognitive Impairment, Alzheimer's Disease
The Swedish BioFINDER Study
The present study aims at combining biochemical methods with various types of imaging techniques to identify the pathophysiology of Alzheimer's disease (AD).
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Dementia With Lewy Bodies, Vascular Dementia
- Trial name
- NCT01208675
- Where
- 2 sites in Sweden
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Frontotemporal Dementia, Dementia
Care of Persons With Dementia in Their Environments (COPE) in Programs of All-Inclusive Care of the Elderly (PACE)
The protocol is organized into three Phases - In Phase I an online training program will be developed in "Care of Persons with Dementia in their Environments" (COPE) -an evidence-based bio-behavioral dementia program -using…
- Conditions
- Frontotemporal Dementia, Dementia, Multi-Infarct Dementia, Vascular Dementia
- Trial name
- NCT04165213
- Testing
- Care of Older Persons in their Environment (COPE) online module training
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Parkinson Disease, Dementia With Lewy Bodies
Optimization of Morphomer-based Alpha-synuclein PET Tracers
The aim of the project is to develop the first alpha-synuclein (a-syn)-specific PET tracer. The research phase will exploit ACI's proprietary MorphomerTM library and extensively optimized screening workflow.
- Conditions
- Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy, Corticobasal Degeneration
- Trial name
- NCT05067192
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Alzheimer Disease, Dementia With Lewy Bodies (DLB)
Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
- Conditions
- Alzheimer Disease, Dementia With Lewy Bodies (DLB), Frontotemporal Dementia (FTD), Major Depressive Disorder (MDD)
- Trial name
- Synapsing-BK (NCT07314190)
- Where
- Spain
- Volunteers
- 1,799 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Parkinson Disease, Prodromal Stage
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases.
- Conditions
- Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases
- Trial name
- ALPHA-FIT (NCT07324330)
- Testing
- Increase of physical activity volume and intensity with the use of a motivational smartphone application
- Where
- Germany
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn